AKT1 and Alzheimer disease: The author proposed that enhanced PKA activity inhibits cRaf-1 (a proto-oncogene serine/threonine-protein kinase) by phosphorylation at serine259, decreasing nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) activity and the expression of NFκB-controlled genes such as BACE1 in the hippocampus of treated AD Tg mice (Arendash et al., 2009).